Colon Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2500
Buy Report View Sample

Published: December 28, 2022 Report Code: GDGMDHC22470IDB-ST

Select Item

Colon Cancer Pipeline Drugs Market Overview

Colon cancer is cancer that starts in the large intestine (colon). There is no single cause of colon cancer. Nearly all colon cancers begin as noncancerous (benign) polyps, which slowly develop into cancer. Many cases of colon cancer have no symptoms. The following symptoms may indicate colon cancer abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, or other change in bowel habits, narrow stools, and weight loss with no known reason. Treatment includes surgery, radiation therapy, and chemotherapy.

The colon cancer pipeline drugs market research report provides comprehensive information on the therapeutics under development for colon cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for colon cancer and features dormant and discontinued projects.

Colon Cancer Pipeline Products Market Segmentation by Targets

The key targets in the colon cancer pipeline products market are Programmed Cell Death Protein 1, Programmed Cell Death 1 Ligand 1, DNA, Tubulin, Adenosine Receptor A2a, DNA Topoisomerase I, Cytotoxic T Lymphocyte Protein 4, and Signal Transducer and Activator of Transcription 3 among others. The Programmed Cell Death Protein 1 is the leading target in the pipeline.

Colon Cancer Pipeline Products Market Analysis by Targets

Colon Cancer Pipeline Products Market Analysis by Targets

For more target insights into the colon cancer pipeline products market, download a free report sample

Colon Cancer Pipeline Products Market Segmentation by Mechanisms of Action

The key mechanisms of action in the colon cancer pipeline products market are Programmed Cell Death 1 Ligand 1 Inhibitor, Programmed Cell Death Protein 1 Antagonist, Tubulin Inhibitor, Adenosine Receptor A2a Antagonist, DNA Synthesis Inhibitor, DNA Topoisomerase I Inhibitor, and Signal Transducer and Activator Of Transcription 3 Inhibitor among others. Programmed Cell Death 1 Ligand 1 Inhibitor is the leading MoA in the pipeline market.

Colon Cancer Pipeline Products Market Analysis by Mechanisms of Action

Colon Cancer Pipeline Products Market Analysis by Mechanisms of ActionFor more mechanisms of action insights into the colon cancer pipeline products market, download a free report sample

Colon Cancer Pipeline Products Market Segmentation by Routes of Administration

The key routes of administration in the colon cancer pipeline products market are oral, subcutaneous, nasal, topical, vaginal, and sublingual among others. Oral is the leading RoA.

Colon Cancer Pipeline Products Market Analysis by Routes of Administration

Colon Cancer Pipeline Products Market Analysis by Routes of AdministrationFor more routes of administration insights into the colon cancer pipeline products market, download a free report sample

Colon Cancer Pipeline Products Market Segmentation by Molecule Types

The key molecule types in the colon cancer pipeline products market are small molecule, monoclonal antibody, cell therapy, synthetic peptide, fusion protein, gene-modified cell therapy, recombinant protein, monoclonal antibody conjugated, oncolytic virus, antisense RNAi oligonucleotide, and recombinant vector vaccine among others. The small molecule is the leading molecule type.

Colon Cancer Pipeline Products Market Analysis by Molecule Types

Colon Cancer Pipeline Products Market Analysis by Molecule TypesFor more molecule type insights into the colon cancer pipeline products market, download a free report sample

Colon Cancer Pipeline Products Market - Competitive Landscape

Some of the leading companies in the colon cancer pipeline products market are Canget BioTekpharma LLC, Diverse Biotech Inc, GO Therapeutics Inc, i2 Pharmaceuticals Inc, WellMarker Bio Co Ltd, BioMed Valley Discoveries Inc, Harbour BioMed (Guangzhou) Co Ltd, Machavert Pharmaceuticals LLC, and Nanjing Aimeifei Biomedical Technology Co Ltd among others. Canget BioTekpharma LLC is the leading company in the colon cancer pipeline products market.

Colon Cancer Pipeline Products Market Analysis by Companies

Colon Cancer Pipeline Products Market Analysis by CompaniesTo know more about the leading players in the colon cancer pipeline products market, download a free report sample

Colon Cancer Pipeline Products Market Report Overview

Key Targets Programmed Cell Death Protein 1, Programmed Cell Death 1 Ligand 1, DNA, Tubulin, Adenosine Receptor A2a, DNA Topoisomerase I, Cytotoxic T Lymphocyte Protein 4, and Signal Transducer and Activator of Transcription 3
Key Mechanisms of Action Programmed Cell Death 1 Ligand 1 Inhibitor, Programmed Cell Death Protein 1 Antagonist, Tubulin Inhibitor, Adenosine Receptor A2a Antagonist, DNA Synthesis Inhibitor, DNA Topoisomerase I Inhibitor, and Signal Transducer and Activator of Transcription 3 Inhibitor
Key Routes of Administration Oral, Subcutaneous, Nasal, Topical, Vaginal, and Sublingual
Key Molecule Type Small Molecule, Monoclonal Antibody, Cell Therapy, Synthetic Peptide, Fusion Protein, Gene-Modified Cell Therapy, Recombinant Protein, Monoclonal Antibody Conjugated, Oncolytic Virus, Antisense RNAi Oligonucleotide, and Recombinant Vector Vaccine
Leading Companies Canget BioTekpharma LLC, Diverse Biotech Inc, GO Therapeutics Inc, i2 Pharmaceuticals Inc, WellMarker Bio Co Ltd, BioMed Valley Discoveries Inc, Harbour BioMed (Guangzhou) Co Ltd, Machavert Pharmaceuticals LLC, and Nanjing Aimeifei Biomedical Technology Co Ltd

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of colon cancer.

  • The pipeline guide reviews pipeline therapeutics for colon cancer by companies and universities/research institutes based on information derived from company and industry-specific sources.

  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.

  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

  • The pipeline guide reviews key companies involved in colon cancer therapeutics and enlists all their major and minor projects.

  • The pipeline guide evaluates colon cancer therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.

  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

  • The pipeline guide reviews the latest news related to pipeline therapeutics for colon cancer

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

  • Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.

  • Find and recognize significant and varied types of therapeutics under development for colon cancer.

  • Classify potential new clients or partners in the target demographic.

  • Develop tactical initiatives by understanding the focus areas of leading companies.

  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.

  • Formulate corrective measures for pipeline projects by understanding the colon cancer pipeline depth and focus on Indication therapeutics.

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

1st Bio Therapeutics Inc
ABL Bio Inc
ABM Therapeutics Inc
Abologix Sarl
Acomhal Research Inc
Actinium Pharmaceuticals Inc
Actym Therapeutics Inc
Adagene Suzhou Ltd
Advenchen Laboratories LLC
Adze Biotechnology Inc
Affimed GmbH
Agastiya Biotech LLC
AgomAb Therapeutics NV
AI Therapeutics Inc
AIGEN Sciences Inc
Alaunos Therapeutics Inc
Alligator Bioscience AB
Alphamab Oncology
Alpine Immune Sciences Inc
Alyra Therapeutics Inc
Amgen Inc
Amrita Therapeutics
ANP Technologies Inc
Antibody Therapeutics Inc
Aphios Corp
Apollomics Inc
AptaBio Therapeutics Inc
Arbutus Biopharma Corp
Ardan Pharma
Ariz Precision Medicine Inc
Ascelia Pharma AB
Ascendis Pharma AS
Ascendo Biotechnology Inc
Ascentawits Pharmaceuticals Ltd
AskAt Inc
Asylia Therapeutics Inc
aTyr Pharma Inc
Aucentra Therapeutics Pty Ltd
Aurigene Discovery Technologies Ltd
Avican Inc
Avidin Biotechnology Ltd
Avidity Biosciences Inc
Azanta A/S
Bayer AG
Baylx Inc
BeiGene Ltd
Beijing FuKangren Bio-pharm Tech Co Ltd
Beijing Weiyuan Likang Biological Technology Co Ltd
BenoBio Co Ltd
BeyondSpring Inc
Binjiang Pharma, Inc.
BioAtla Inc
Biocytogen Pharmaceuticals (Beijing) Co Ltd
Biogazelle NV
BioMed Valley Discoveries Inc
Biomunex Pharmaceuticals
BioXpress Therapeutics SA
Bliss Biopharmaceutical (Hangzhou) Co Ltd
Blueprint Medicines Corp
Boehringer Ingelheim International GmbH
Bold Therapeutics Inc
BoYen Therapeutics Inc
Bristol-Myers Squibb Co
Calidi Biotherapeutics Inc
Can-Fite BioPharma Ltd
CanBas Co Ltd
Cancure Ltd
Canget BioTekpharma LLC
Cantargia AB
Carina Biotech Pty Ltd
CEFO Co Ltd
Celldex Therapeutics Inc
Cellective BioTherapy Inc
Celprogen Inc
Center for Genetic Engineering and Biotechnology
Centrymed Pharmaceutical Inc
Changchun Huapu Biotechnology Co Ltd
Chengdu Huitai Biomedicine Co Ltd
Chengdu Jinrui Foundation Biotechnology Co Ltd
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Chinook Therapeutics Inc
Claradele Pharmaceuticals Inc
CMG Pharmaceutical Co Ltd
CNCure Biotech Inc
Coastar Therapeutics LLC
Codiak BioSciences Inc
Coherent Biopharma
Cosmo Pharmaceuticals NV
CStone Pharmaceuticals Co Ltd
Cureport Inc
CV6 Therapeutics (Ni) Ltd
Cytodyn Inc
CytomX Therapeutics Inc
CZ BioMed Corp
Defence Therapeutics Inc
DEKK-TEC Inc
Diazon Pharmaceuticals Inc
DiNonA Inc
Disulfican Ltd
Diverse Biotech Inc
Dracen Pharmaceuticals Inc
Dragonboat Biopharmaceutical (Shanghai) Co Ltd
Duet Therapeutics Inc
eFFECTOR Therapeutics Inc
Eisai Co Ltd
Eli Lilly and Co
Elicera Therapeutics AB
Elixiron Immunotherapeutics Inc
Elucida Oncology Inc
Emcure Pharmaceuticals Ltd
Enara Bio Ltd
EncuraGen Co Ltd
Enochian Biosciences Inc
EnzymeBioSystems
Epigene Therapeutics Inc
Eucure (Beijing) Biopharma Co Ltd
Evestra Inc
Evgen Pharma Plc
Evopoint Bioscience Co Ltd
F. Hoffmann-La Roche Ltd
Felicitex Therapeutics Inc
For-Robin Inc
Frontbio Co Ltd
Fujifilm Holdings Corp
GC Biopharma Corp
GeneLeap Biotech
Genexine Inc
GeoVax Labs Inc
Ginkgo BioWorks Inc
GlycaNova AS
GlyTR Therapeutics Inc
GO Therapeutics Inc
GSK plc
Guangzhou BeBetter Medicine Technology Co Ltd
HaimBio Ltd
Hamlet Pharma AB
Hangzhou Bensheng Pharmaceutical Co Ltd
Harbour BioMed (Guangzhou) Co Ltd
Horizon Therapeutics Plc
Hummingbird Bioscience Pte Ltd
i2 Pharmaceuticals Inc
Ikena Oncology Inc
Ildong Pharmaceutical Co Ltd
ImCheck Therapeutics SAS
Immix BioPharma Inc
Immune Modulation Inc
ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
ImmunityBio Inc
Immunos Therapeutics AG
Immvira Co Ltd
IMPACT Therapeutics Inc
Imugene Ltd
inCerebro Co Ltd
Infinity Pharmaceuticals Inc
Inmune Bio Inc
Innate Pharma SA
InnoCare Pharma Ltd
Innopharmax Inc
Intensity Therapeutics Inc
iOmx Therapeutics AG
iOnctura SA
Ipsen SA
Ix Therapeutics GmbH
J-Pharma Co Ltd
JenKem Technology Co Ltd
Jiangsu Atom Bioscience and Pharmaceutical Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Jiangsu Kanion Pharmaceutical Co Ltd
Jina Pharmaceuticals Inc
JN Biosciences LLC
Jubilant Therapeutics Inc
JW Pharmaceutical Corp
Kadmon Holdings Inc
KAHR medical Ltd
Kazia Therapeutics Ltd
Kintara Therapeutics Inc
Kringle Pharma Inc
Laekna Therapeutics Shanghai Co Ltd
Linnane Pharma AB
LipoSeuticals Inc
Lixte Biotechnology Holdings Inc
Luzitin SA
Machavert Pharmaceuticals LLC
MacroGenics Inc
Marine Biomedical Research Institute of Qingdao
MaxiVAX SA
Medicenna Therapeutics Corp
Medicon Pharmaceuticals Inc
Medigen Biotechnology Corp
MedPacto Inc
Mendus AB
Merck & Co Inc
MicroQuin Ltd
Midissia Therapeutics Inc
Mito BioPharm LLC
Mosaic ImmunoEngineering Inc
Multimmune GmbH
MultiVir Inc
Myeloid Therapeutics Inc
Nammi Therapeutics Inc
Nanjing Aimeifei Biomedical Technology Co Ltd
Nascent Biotech Inc
NED Biosystems Inc
Nektar Therapeutics
Netris Pharma SAS
Nimbus Therapeutics LLC
Novartis AG
Nutshell Therapeutics Inc
OBiO Technology (Shanghai) Corp Ltd
Oceanyx Pharmaceuticals Inc
Oita University Institute of Advanced Medicine Inc
Omeros Corp
Oncocross Co Ltd
Oncology Pharma Inc
Oncolyze Inc
Oncovir Inc
Oncoxx Biotech Srl
Oneness Biotech Co Ltd
Ono Pharmaceutical Co Ltd
Orano Med LLC
Orpheus Therapeutics Inc
Oryn Therapeutics
Pacylex Pharmaceuticals Inc
Papyrus Therapeutics Inc
Parasol Biotech Co Ltd
Pathios Therapeutics Ltd
Patrys Ltd
PAZ Pharma
Pfizer Inc
PharmAbcine Inc
Phenex Pharmaceuticals AG
Phio Pharmaceuticals Corp
Photolitec LLC
PHusis Therapeutics Inc
Pionyr Immunotherapeutics Inc
PNB Vesper Life Science Pvt Ltd
PolyPid Ltd
Portage Biotech Inc
Primetime Life Sciences LLC
Propanc Biopharma Inc
Prosetta Biosciences Inc
Protexase Therapeutics Inc
Provecs Medical GmbH
Provectus Biopharmaceuticals Inc
PsiOxus Therapeutics Ltd
PTM Therapeutics Inc
Pylum Biosciences Inc
Qilu Puget Sound Biotherapeutics Corp
Qu Biologics Inc
Ranger Biotechnologies AS
Riptide Bioscience Inc
Sagimet Biosciences Inc
Sanofi
Sareum Holdings Plc
Savoy Pharmaceuticals Inc
Schrodinger Inc
SEEKYO Therapeutics
Senex Biotechnology
SetLance srl
Shanghai Fosun Pharmaceutical (Group) Co Ltd
Shanghai GeneChem Co Ltd
Shattuck Labs Inc
Shenzhen Chipscreen Biosciences Co Ltd
Shionogi & Co Ltd
Sichuan Huiyang Life Science and Technology Corp
SideROS
SignPath Pharma Inc
Simcere Pharmaceutical Group Ltd
SIRPant Immunotherapeutics Inc
Somantix BV (Inactive)
Soricimed Biopharma Inc
Sorrento Therapeutics Inc
SOTIO Biotech AS
Sparx Therapeutics Inc
Sphaera Pharma Pte Ltd
Statera Biopharma Inc
Stcube Inc
Stingray Therapeutics LLC
Sumitomo Pharma Co Ltd
Suzhou Stainwei Biotech Inc
Syncromune Inc
TAE Life Sciences LLC
Taiho Pharmaceutical Co Ltd
Takis Srl
Tango Therapeutics Inc
TargaGenix Inc
Tarus Therapeutics Inc
TenCure Ltd
TheraBioPharma Inc
Theravectys SA
Tianjin Hengjia Biotechnology Development Co Ltd
Tiziana Life Sciences Plc
Toray Industries Inc
Totus Medicines Inc
Transcenta Holding Ltd
Transgene Biotek Ltd
TVAX Biomedical Inc
Twist Bioscience Corp
Tychon Bioscience Inc
Tyg Oncology Ltd
Tyme Inc
United Immunity Co Ltd
Vascular Biogenics Ltd
Vault Pharma Inc
Viomedix LLC
Viracta Therapeutics Inc
Virocure Inc
Virogin Biotech Ltd
WellMarker Bio Co Ltd
Werewolf Therapeutics Inc
Westwood Bioscience Inc
WindMIL Therapeutics Inc
WntResearch AB
Wuhan YZY Biopharma Co Ltd
Wuxi Zhikang Hongyi Biological Technology Co Ltd
XOMA Corp
Y-mAbs Therapeutics Inc
Yuhan Corp
Zenith Epigenetics Ltd
Zovis Pharmaceuticals

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Colon Cancer – Overview

Colon Cancer – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Colon Cancer – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Colon Cancer – Companies Involved in Therapeutics Development

Colon Cancer – Drug Profiles

Colon Cancer – Dormant Projects

Colon Cancer – Discontinued Products

Colon Cancer – Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Colon Cancer, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Colon Cancer – Dormant Projects, 2022

Colon Cancer – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Colon Cancer, 2022

Number of Products under Development by Companies, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently asked questions

Colon Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update standard reports
Currency USD
$2,500

Can be used by individual purchaser only

Most Popular
$5,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$7,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Colon Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Oncology reports
Pharmaceuticals
New
HER2-Positive Breast Cancer Epidemiology Analysis and Forecast to 2033
$3,995 | May 2024
Pharmaceuticals
New
Pharma M&A Deals Q1 2024 - Top Themes - Thematic…
$995 | May 2024
Pharmaceuticals
New
Friedreich Ataxia (FRDA) Marketed and Pipeline Drugs Assessment, Clinical Trials…
$3,495 | April 2024
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Colon Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Colon Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more